Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.
PMID: 26651266
2016
AIDS research and human retroviruses
Method: In addition, we defined a list of minor RPV-RAMs that have been observed in in vitro or in vivo selection studies and are included in one or more of clinically widely used genotypic resistance interpretation algorithms ANRS (V24), Rega (V9.1.0), and HIVdb (V7.0.1), encompassing V90I, A98G, L100I/V, K101H/Q/T, K103R/S, V106A/I, V108I, E138S, V179D/E/F/I/T, Y181F/G/S, Y188F, V189I, G190A/C/E/Q/S/T/V, and M230V
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
Epidemiological and molecular characteristics of HIV infection among money boys and general men who have sex with men in Shanghai, China.
PMID: 25653132
2015
Infection, genetics and evolution
Result: Several minor mutations were detected in the protease (PR) region of the pol gene: L10I (3.8%), V11I (1.9%), L33F (1.9%) and A71T/V (17.3%); and several others were detected in the reverse transcriptase (RT) region of the pol gene: T69A (1.9%), V118I (11.5%), L210M (1.9%), V179I (11.5%) and K101Q (1.9%).
Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.
PMID: 25582324
2015
AIDS research and human retroviruses
Result: We also detected NRTI selected mutations M41L, E44D, T69ANS, V75M, and V118I, and NNRTI mutations V90I, A98G, K101EQ, K103NR, V106I, V108I, E138A, V179EI, and G190A (Table 3).
HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naive MSM from 2011 to 2013 in Beijing, China.
Discussion: In another study by our team, we had applied the CorMut algorithm to investigate the association between drug resistance and compensatory mutations, and demonstrated that K101Q, H221Y, and T139K can enhance K103N/Y181C/G190A-associated NNRTI-resistance among CRF07_BC in vitro.
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
PMID: 25114163
2014
The Journal of antimicrobial chemotherapy
Abstract: Five genotypes were determined during the follow-up, revealing three rilpivirine resistance-associated mutations: E138Q/Y181I, M230L and K101P (potentially with a K101Q intermediate).
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Abstract: BACKGROUND: The aim of this study was to investigate the role of K101Q, Y181C and H221Y emerging in HIV-1 reverse transcriptase with different mutations patterns in phenotypic susceptibility to currently available NNRTIs (nevirapine NVP, efavirenz EFV) and NRTIs (zidovudine AZT, lamivudine 3TC, stavudine d4T) in China.
Abstract: Certainly, the double mutation (K101Q/H221Y) also changes the susceptibility of viruses to NRTIs.
Abstract: Remarkably, K101Q/H221Y was hypersusceptible to EFV (FC = 0.04), but was significantly resistant to the three NRTIs
Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains.
Abstract: K101Q, H221Y and T139K can enhance K103N/Y181C/G190A-assocated NNRTI-resistance.
Abstract: Result showed that eight polymorphic mutations (W88C, K101Q, I132L, R135L, T139K/R, H221Y and L228R) in RT for treatment-experienced patients were identified, while they, except for R135L, were completely absent in those from treatment-naive patients.
Abstract: The I132L and
HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study.
HIV mutation literature information.
PMID: 
2016
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT